Hinokitiol Inhibits Breast Cancer Cells In Vitro Stemness-Progression and Self-Renewal with Apoptosis and Autophagy Modulation via the CD44/Nanog/SOX2/Oct4 Pathway

• Published in: International journal of molecular sciences 2024-04, Vol.25 (7), p.3904
• Main Authors: Chiang, Yi-Fen, Huang, Ko-Chieh, Chen, Hsin-Yuan, Hamdy, Nadia M, Huang, Tsui-Chin, Chang, Hsin-Yi, Shieh, Tzong-Ming, Huang, Yun-Ju, Hsia, Shih-Min
• Format: Article
• Language: English
• Subjects: Apoptosis; Autophagy; Breast cancer; breast cancer stem cell; Breast Neoplasms - drug therapy; Cancer cells; Cancer therapies; CD44; Cell cycle; Chemotherapy; Estrogens; Ethylenediaminetetraacetic acid; Female; hinokitiol; Humans; Hyaluronan Receptors; Kinases; MCF-7 Cells; Medical research; Medicine, Experimental; Metastasis; Monoterpenes; Neoplasm Recurrence, Local; Protein expression; Proteins; Signal transduction; SOXB1 Transcription Factors; Stem cells; Tropolone - analogs & derivatives; Tropolone - pharmacology; Tumor proteins
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25073904

Breast cancer (BC) represents one of the most prevalent malignant threats to women globally. Tumor relapse or metastasis is facilitated by BC stemness progression, contributing to tumorigenicity. Therefore, comprehending the characteristics of stemness progression and the underlying molecular mechanisms is pivotal for BC advancement. Hinokitiol (β-thujaplicin), a tropolone-related compound abundant in the heartwood of cupressaceous plants, exhibits antimicrobial activity. In our study, we employed three BC cell lines (MDA-MB-231, MCF-7, and T47D) to assess the expression of stemness-, apoptosis-, and autophagy-related proteins. Hinokitiol significantly reduced the viability of cancer cells in a dose-dependent manner. Furthermore, we observed that hinokitiol enhances apoptosis by increasing the levels of cleaved poly-ADP-ribose polymerase (PARP) and phospho-p53. It also induces dysfunction in autophagy through the upregulation of LC3B and p62 protein expression. Additionally, hinokitiol significantly suppressed the number and diameter of cancer cell line spheres by reducing the expression of cluster of differentiation44 (CD44) and key transcription factors. These findings underscore hinokitiol's potential as a therapeutic agent for breast cancer, particularly as a stemness-progression inhibitor. Further research and clinical studies are warranted to explore the full therapeutic potential of hinokitiol in the treatment of breast cancer.